-32.5%
NVDL vs MRNA
+909.7%
-942.2%
-47.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -18.6% | -6.5% | -12.0% | -18.5% |
| 7D | -28.8% | +8.4% | -37.2% | -28.8% |
| 30D | -44.0% | +28.8% | -72.8% | -44.0% |
| 3M | -35.6% | +329.2% | -364.8% | -36.6% |
| 6M | -25.3% | +416.9% | -442.2% | -30.8% |
| YTD | -23.3% | +718.8% | -742.1% | -29.1% |
| 1Y | -32.5% | +924.9% | -957.4% | -36.5% |
| All | -32.5% | +909.7% | -942.2% | -36.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling